YOLFTbeta
SAB Biotherapeutics Inc

SAB Biotherapeutics Inc

SABS · NASDAQ · Healthcare / Biotechnology

2.96USD-0.12 (-3.90%)

Price History

Full chart

Market Stats

Previous Close3.08
Open3.08
Day Range2.85 – 3.15
52-Week Range1.91 – 5.15
Volume658.12K
Market Cap299.35M
P/E (TTM)13.71
Forward P/E0.00
EPS0.24
Dividend Yield0.00%
Beta0.54
50-Day Avg3.64
200-Day Avg3.79

About

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Samuel J. Reich
  • Employees86
  • Headquarters777 W 41st St., Miami Beach, FL, United States, 33140, USA
  • Websitehttps://www.sab.bio

Leadership

  • Mr. Samuel J. ReichCEO & Director · b. 1975
  • Dr. Eddie Joe Sullivan Ph.D.Co-Founder, President & Director · b. 1967
  • Ms. Lucy ToExecutive VP & CFO · b. 1986
  • Dr. Christoph Bausch M.B.A., Ph.D.Executive VP & COO · b. 1971
  • Dr. Alexandra Kropotova M.B.A., M.D.Executive VP & Chief Medical Officer · b. 1973
  • Ms. Catherine DeRoseVice President of Human Resources
  • Ms. Hua Wu Ph.D.Senior Vice President of Product Development
  • Dr. Carlos N. Carillo M.Sc., Ph.D.Senior Vice President of Regulatory Affairs
  • Ms. Angie ParizekSenior Vice President of Clinical Operations

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.44M55.24M60.88M23.90M2.24M1.32M0
Growth (%)-+1504.82%+10.21%-60.73%-90.63%-40.94%-100.00%
Cost of Revenue--1.65M3.29M3.75M4.79M3.08M
Gross Profit3.44M55.24M59.22M20.61M-1.51M-3.47M-3.08M
Gross Margin100.00%100.00%97.28%86.23%-67.26%-262.41%-
Operating Expense12.12M34.68M72.61M49.53M36.57M39.44M45.87M
Operating Income-8.67M20.56M-13.39M-28.92M-38.08M-42.91M-48.95M
Operating Margin-252.00%37.22%-22.00%-120.98%-1700.54%-3244.87%-
EBITDA-8.23M21.14M-15.20M-15.12M-38.13M-28.99M16.60M
EBITDA Margin-239.22%38.26%-24.96%-63.26%-1703.13%-2192.54%-
Net Income-8.99M20.12M-17.14M-18.74M-42.19M-34.11M13.27M
Net Income Margin-261.07%36.42%-28.16%-78.40%-1884.50%-2579.03%-
R&D8.02M27.91M57.18M36.44M16.52M30.16M34.35M
R&D as % of Total Revenue233.00%50.53%93.94%152.44%737.61%2281.05%-
Interest Expense428.48K469.15K294.46K301.58K315.28K318.40K240.66K
Interest Expense % of Total Revenue12.45%0.85%0.48%1.26%14.08%24.08%-

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets18.00M56.54M81.14M50.90M83.94M44.20M172.81M
Total Liabilities20.31M17.53M42.59M19.85M26.64M18.23M21.32M
Total Equity-2.31M39.01M38.55M31.06M57.30M25.97M151.49M
Cash6.35M12.61M33.21M15.05M56.57M8.90M10.50M
Total Debt7.64M8.13M8.52M5.93M5.91M4.67M5.95M
Net Debt1.29M-4.48M-24.69M-9.12M-50.66M-4.23M-4.55M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-9.21M10.00M1.99M-23.46M-25.12M-34.29M-44.78M
Investing Cash Flow-608.75K-12.72M-10.94M-2.09M-152.70K-11.96M-121.71M
Financing Cash Flow3.68M8.98M35.89M1.05M66.77M-1.17M168.30M
Capital Expenditure608.75K12.73M10.94M2.17M197.15K337.26K933.15K
Free Cash Flow-9.82M-2.73M-8.96M-25.63M-25.32M-34.63M-45.71M
FCF to OCF106.61%-27.26%-450.80%109.23%100.78%100.98%102.09%

Earnings

Report DateMay 21, 2021Aug 9, 2021Nov 22, 2021Mar 29, 2022May 12, 2022Aug 10, 2022Nov 14, 2022Mar 31, 2023May 15, 2023Aug 21, 2023Nov 13, 2023Mar 29, 2024May 20, 2024Aug 8, 2024Nov 6, 2024Mar 26, 2025May 9, 2025Aug 7, 2025Nov 14, 2025Mar 9, 2026May 12, 2026Aug 6, 2026Nov 13, 2026
EPS Estimate---0.60-0.11-1.10-1.00-1.10-0.16-1.00-1.45-1.15-0.62-0.98-1.15-1.09-1.21-1.07-0.82-0.46-0.17-0.21-0.29-0.27
EPS Actual0.84-0.03-1.20-0.66-1.35-1.50-1.83-0.16-1.48-1.29-1.01-3.38-1.14-0.79-1.12-0.98-0.56-1.090.50-0.41-0.35-0.28-
Surprise---100.00%-500.00%-22.73%-50.00%-66.36%0.00%-48.00%11.03%12.17%-445.16%-16.33%31.30%-2.75%18.93%47.66%-32.93%208.70%-141.18%-69.38%3.45%-
TimingAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hours-Pre-market-

Key Statistics & Ratios

Market Cap299.35M
Enterprise Value211.40M
Trailing P/E13.71
Forward P/E0.00
Price / Sales2.96
Price / Book1.48
EPS0.24
Book Value2.57
Revenue (TTM)114.70K
Gross Profit (TTM)-48.27M
EBITDA-68.71M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-11.27%
Return on Assets-33.46%
Shares Outstanding90.99M
Shares Float62.04M
Beta0.54
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 5 analystsTarget 11.64
  • Strong Buy
    4
  • Buy
    1

Ownership Breakdown

Institutions
75.43%
Insiders
0.71%
Retail / Other
23.86%

Top Institutional Holders

  • Caligan Partners LP
    7.97M8.76%
  • Vivo Capital, LLC
    7.30M8.02%
  • Perceptive Advisors LLC
    6.63M7.28%
  • Adage Capital Partners Gp LLC
    6.41M7.04%
  • RA Capital Management, LLC
    4.40M4.84%
  • COMMODORE CAPITAL LP
    4.40M4.84%
  • Balyasny Asset Management LLC
    3.76M4.13%
  • Woodline Partners LP
    2.85M3.13%
  • Millennium Management LLC
    2.75M3.02%
  • Vanguard Capital Management, LLC
    2.49M2.74%
  • Spruce Street Capital LP
    2.20M2.42%
  • Sessa Capital, L.P
    2.20M2.42%
  • Affinity Asset Advisors, LLC
    1.52M1.68%
  • BOOTHBAY FUND MANAGEMENT, LLC
    1.48M1.63%
  • Ameriprise Financial Inc
    1.48M1.62%
  • Ensign Peak Advisors Inc
    1.38M1.51%
  • Propel Bio Management LLC
    1.08M1.18%
  • Jefferies Financial Group Inc
    903.09K0.99%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    2.26M2.48%
  • iShares Russell 2000 ETF
    1.04M1.14%

Stock Splits

  • Jan 5, 20241:10